Syapse, a Palo Alto, CA-based company enabling healthcare systems to implement precision medicine programs has raised $25 million in Series C funding led by Ascension Ventures, a subsidiary of Ascension, the nation's largest non-profit and Catholic health system. Existing investors Social Capital Partnership and Safeguard Scientifics also participated in this new funding round. The company will use this funding round to drive the rapid expansion of its Syapse Precision Medicine
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Assurex Health Nabs $15M for Precision Medicine for Behavioral Health
Assurex Health, Inc., a commercial-stage, informatics-based precision medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions, has secured an additional $15 million in equity funding. Assurex Health’s proprietary technology is based on pharmacogenomics— the study of the genetic factors that influence an individual’s response to drug treatments—as well as evidence-based medicine and clinical pharmacology. The GeneSight
Read More
Meaningful Use Stage 3 Proposed Rule: 5 Takeaways for Physicians
On March 20, 2015 the stars aligned to produce four simultaneous events that will never again coincide during the life of human civilization. The first three, the vernal equinox, a total solar eclipse and a new supermoon, were brought to us by the stars themselves, and the fourth one was thrown out there by the government. The regulations for Meaningful Use Stage 3 were finally published. Meaningful use of electronic health records (EHR) was presented to us back in 2009 as part of a stimulus
Read More
